Interpace Biosciences, Inc. (IDXG) stock
IDXGOTCSurgical & Medical Instruments & ApparatusFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 16, 2026Score 10/30
$5.00−0.15 (-2.91%)
Close on Oct 19, 2026Market cap $138.57MP/E 5.6Yield –
Interpace Biosciences profit margin
Profit margin (net margin) is net income as a percentage of revenue.
Interpace Biosciences's profit margin for the twelve months ending Jun 30, 2026 was 67.6%. For fiscal 2025 it was 63.5%, against 14.3% the year before. The highest annual figure on record is 79.0% in fiscal 2017.
Annual profit margin
| Period | Period end | Value | Change (pts) |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | 63.5% | +49.2 |
| FY2024 | Dec 31, 2024 | 14.3% | +9.4 |
| FY2023 | Dec 31, 2023 | 4.9% | +73.8 |
| FY2022 | Dec 31, 2022 | -69.0% | +113.3 |
| FY2021 | Dec 31, 2021 | -182.3% | −100.7 |
| FY2020 | Dec 31, 2020 | -81.6% | +28.8 |
| FY2019 | Dec 31, 2019 | -110.4% | −52.4 |
| FY2018 | Dec 31, 2018 | -58.0% | −137.0 |
| FY2017 | Dec 31, 2017 | 79.0% | +247.1 |
| FY2016 | Dec 31, 2016 | -168.2% | −23.7 |
| FY2015 | Dec 31, 2015 | -144.4% | +993.2 |
| FY2014 | Dec 31, 2014 | -1137.6% | −1134.5 |
| FY2013 | Dec 31, 2013 | -3.1% | +17.0 |
| FY2012 | Dec 31, 2012 | -20.1% | −12.5 |
| FY2011 | Dec 31, 2011 | -7.6% | −2.5 |
| FY2010 | Dec 31, 2010 | -5.1% | – |
Quarterly profit margin
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change (pts) |
|---|---|---|---|
| Q2 FY2026 | Jun 30, 2026 | 1.7% | +8.7 |
| Q1 FY2026 | Mar 31, 2026 | 8.0% | −6.3 |
| Q4 FY2025 | Dec 31, 2025 | 245.6% | +230.5 |
| Q3 FY2025 | Sep 30, 2025 | 10.4% | −3.2 |
| Q2 FY2025 | Jun 30, 2025 | -6.9% | −27.2 |
| Q1 FY2025 | Mar 31, 2025 | 14.3% | +7.3 |
| Q4 FY2024 | Dec 31, 2024 | 15.2% | +4.6 |
| Q3 FY2024 | Sep 30, 2024 | 13.6% | +15.7 |
| Q2 FY2024 | Jun 30, 2024 | 20.2% | +15.2 |
| Q1 FY2024 | Mar 31, 2024 | 7.0% | +1.6 |
| Q4 FY2023 | Dec 31, 2023 | 10.5% | +16.5 |
| Q3 FY2023 | Sep 30, 2023 | -2.0% | +1119.4 |
| Q2 FY2023 | Jun 30, 2023 | 5.1% | +206.4 |
| Q1 FY2023 | Mar 31, 2023 | 5.3% | +96.9 |
| Q4 FY2022 | Dec 31, 2022 | -6.0% | +15.6 |
| Q3 FY2022 | Sep 30, 2022 | -1121.4% | −1077.2 |
| Q2 FY2022 | Jun 30, 2022 | -201.4% | −170.5 |
| Q1 FY2022 | Mar 31, 2022 | -91.6% | −48.8 |
| Q4 FY2021 | Dec 31, 2021 | -21.5% | +62.9 |
| Q3 FY2021 | Sep 30, 2021 | -44.2% | +31.4 |
| Q2 FY2021 | Jun 30, 2021 | -30.9% | +71.6 |
| Q1 FY2021 | Mar 31, 2021 | -42.8% | +28.9 |
| Q4 FY2020 | Dec 31, 2020 | -84.4% | +168.6 |
| Q3 FY2020 | Sep 30, 2020 | -75.6% | +20.8 |
| Q2 FY2020 | Jun 30, 2020 | -102.5% | −17.9 |
| Q1 FY2020 | Mar 31, 2020 | -71.7% | −16.3 |
| Q4 FY2019 | Dec 31, 2019 | -253.0% | −179.3 |
| Q3 FY2019 | Sep 30, 2019 | -96.4% | −42.1 |
| Q2 FY2019 | Jun 30, 2019 | -84.6% | −48.2 |
| Q1 FY2019 | Mar 31, 2019 | -55.3% | +12.8 |
| Q4 FY2018 | Dec 31, 2018 | -73.7% | −525.9 |
| Q3 FY2018 | Sep 30, 2018 | -54.3% | +26.6 |
| Q2 FY2018 | Jun 30, 2018 | -36.4% | +129.4 |
| Q1 FY2018 | Mar 31, 2018 | -68.1% | −135.3 |
| Q4 FY2017 | Dec 31, 2017 | 452.2% | +688.9 |
| Q3 FY2017 | Sep 30, 2017 | -80.9% | +160.4 |
| Q2 FY2017 | Jun 30, 2017 | -165.8% | – |
| Q1 FY2017 | Mar 31, 2017 | 67.1% | – |
| Q4 FY2016 | Dec 31, 2016 | -236.7% | – |
| Q3 FY2016 | Sep 30, 2016 | -241.3% | – |
See a number that looks wrong?